Invesco
CSTL icon

Invesco’s Castle Biosciences CSTL Stock Holding History

Invesco’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.5M Sell
61,012
-74,449
-55% -$2.44M ﹤0.01% 2685
2025
Q4 		$5.27M Buy
135,461
+79,621
+143% +$2.57M ﹤0.01% 2227
2025
Q3 		$1.27M Buy
55,840
+15,411
+38% +$313K ﹤0.01% 2824
2025
Q2 		$826K Buy
40,429
+8,178
+25% +$151K ﹤0.01% 2926
2025
Q1 		$646K Buy
32,251
+4,717
+17% +$117K ﹤0.01% 3049
2024
Q4 		$734K Buy
27,534
+616
+2% +$18.8K ﹤0.01% 3048
2024
Q3 		$768K Sell
26,918
-130
-0.5% -$3.31K ﹤0.01% 3030
2024
Q2 		$589K Sell
27,048
-348
-1% -$7.75K ﹤0.01% 3208
2024
Q1 		$607K Sell
27,396
-4,760
-15% -$104K ﹤0.01% 3235
2023
Q4 		$694K Sell
32,156
-3,801
-11% -$66.9K ﹤0.01% 3058
2023
Q3 		$607K Buy
35,957
+12,238
+52% +$214K ﹤0.01% 3110
2023
Q2 		$325K Buy
23,719
+814
+4% +$16.5K ﹤0.01% 3463
2023
Q1 		$520K Buy
22,905
+3,782
+20% +$92.4K ﹤0.01% 3242
2022
Q4 		$450K Sell
19,123
-326,856
-94% -$7.58M ﹤0.01% 3325
2022
Q3 		$9.02M Sell
345,979
-2,883
-0.8% -$80.8K ﹤0.01% 1867
2022
Q2 		$7.66M Sell
348,862
-730,170
-68% -$17M ﹤0.01% 2026
2022
Q1 		$48.4M Buy
1,079,032
+29,372
+3% +$1.21M 0.01% 1021
2021
Q4 		$45M Buy
1,049,660
+18,002
+2% +$941K 0.01% 1089
2021
Q3 		$68.6M Sell
1,031,658
-106,594
-9% -$7.5M 0.02% 930
2021
Q2 		$83.5M Buy
1,138,252
+111,547
+11% +$7.37M 0.02% 898
2021
Q1 		$70.3M Sell
1,026,705
-92,418
-8% -$6.95M 0.02% 928
2020
Q4 		$75.1M Buy
1,119,123
+1,035,819
+1,243% +$56.1M 0.02% 868
2020
Q3 		$4.29M Buy
83,304
+66,367
+392% +$2.95M ﹤0.01% 2079
2020
Q2 		$638K Buy
+16,937
New +$579K ﹤0.01% 3017

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco's CSTL Position: Q1 2026 in Review

Invesco reduced its Castle Biosciences (CSTL) stake by 55% in Q1 2026, selling an estimated $2.44M and leaving 61,012 shares worth $1.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2685.

Invesco first reported a position in CSTL in Q2 2020 and has held it in 24 quarters since. The position peaked at $83.5M in Q2 2021. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Invesco held 61,012 shares of Castle Biosciences worth $1.5M as of Q1 2026.
  • Invesco sold 74,449 Castle Biosciences shares in Q1 2026, an estimated $2.44M.
  • Castle Biosciences made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #2685 holding.
  • Invesco first reported a position in Castle Biosciences in Q2 2020 and has held it in 24 quarters since.
  • Invesco's Castle Biosciences position peaked at $83.5M in Q2 2021.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.